This educational enduring activity provides ophthalmology clinicians with the opportunity to recognize the burden of anti-VEGF therapy on patients, its impact on adherence, and integrate new research about therapeutic strategies in nAMD and DME. The program aims to provide participants with strategies to reduce treatment burden for patients through longer treatment intervals in order to optimize outcomes. Recent clinical trial data is analyzed on the differences between conventional and next generation anti-VEGF agents, and participants will learn more about dosing strategies through an augmented reality animation.

RELEASED DATE: June 14, 2024
EXPIRATION DATE: June 14, 2025

This enduring activity targets healthcare gaps related to awareness of health disparities in the prevention and treatment of ocular diseases and the importance of diverse representation within clinical trials and the ophthalmology workforce, impacting outcomes through assessing for factors that can contribute to disparities in vision health and strategies to overcome them.

This online program targets critical issues in diabetic retinopathy, including the importance of screening and early detection of retinopathy, how early treatment in retinopathy can help prevent progression to vision-threatening complications, and the advantageous impact of multidisciplinary management in the care of a retinopathy patient. Learn essential elements of screening, referral, and treatment, as well as core systemic factors affecting risk for both development and worsening of diabetic eye disease, which when optimized can help preserve vision in diabetes.

This enduring program about retinopathy of prematurity (ROP) targets key concepts about pathophysiology and the role of vascular endothelial growth factor (VEGF), screening, and management for this potentially visually blinding disorder of premature infants. Learn essential elements for recognizing infants at risk, timelines to ROP development, current advances in treatment approaches and critical examination timeframes to help prevent progression as well as complications of advanced disease.

This enduring activity targets healthcare gaps related to the early intervention of retinal vascular diseases and familiarity with new and emerging clinical trial data, impacting outcomes through assessment and synthesis of clinical trial structures, and outcomes of studied anti-VEGF agents for incorporation into treatment strategy development.

This enduring program targets critical issues in nonproliferative diabetic retinopathy (NPDR), including risk for retinopathy development and progression, how early treatment can help prevent progression to vision-threatening complications, and treatment strategies for NPDR. Learn essential elements of assessment and management, as well as clinical trial data on the latest approaches in care, helping to preserve vision in diabetes.

This podcast series aims to increase the target clinicians’ awareness of gaps and burdens associated with treatment of ocular disorders such as nAMD and DME, contributing to poorer vision outcomes. Learn about unmet needs in the treatment of nAMD and DME, enhance appreciation of barriers to anti-VEGF treatment, and acquire tactics to address these barriers through individualized approaches to treatment such as dosing strategies and next-generation anti-VEGF therapy.

RELEASED DATE: October 01, 2024
EXPIRATION DATE: October 11, 2025

This enduring activity offers a unique and immersive approach to understanding the impact of anti-VEGF therapy for the treatment of diabetic macular edema (DME). Step into the world of a patient facing the burden of treatment and gain insight into the challenges they encounter. Providers will learn about the durability of established and emerging DME therapies and how frequent treatment intervals can impact patient outcomes, as well as providing a personal perspective on the different challenges that patients can face. This activity uses a unique documentary approach to share a patient’s story, along with commentary from a retinal disease expert.

RELEASED DATE: December 01 2024
EXPIRATION DATE: December 01, 2025

This enduring educational program aims to increase clinicians’ awareness of gaps and burdens associated with treatment of diabetic macular edema (DME) that can contribute to poorer vision outcomes. Along with didactic presentation, this activity will include small group case-study discussions to provide retina specialists and comprehensive ophthalmologists will acquire knowledge and tactics to address these barriers through individualized approaches to treatment, such as dosing strategies and use of next-generation anti-VEGF therapy. Featuring a panel discussion to enhance the practical integration of addressing treatment burden.

RELEASED DATE: December 01, 2024
EXPIRATION DATE: December 01, 2025

This program will offer ophthalmologists and retina specialties the opportunity to integrate research about barriers to care that contribute to poorer vision outcomes in treatment of diabetic macular edema (DME). This activity will have didactic presentation and case-based discussions to acquire knowledge, tactics to address these barriers, and optimize outcomes through individualized approaches to treatment, including dosing strategies and use of next-generation anti-VEGF therapy. An animated whiteboard enhances comprehension of the mechanisms of anti-VEGF therapy and demonstrates how expanded dosing intervals available through next-generation anti-VEGF therapy can help reduce the burden of care.

RELEASED DATE: December 13, 2024
EXPIRATION DATE: December 13, 2025